Geographical Differences of Carbapenem Non-susceptible Enterobacterales and Acinetobacter Spp. in Germany from 2017 to 2019

Overview

Journal Antimicrob Resist Infect Control

Publisher Biomed Central

Specialty Infectious Diseases

Date 2022 Feb 5

PMID 35120555

Authors

Anja von Laer

Tim Eckmanns

Benedikt Zacher

Niels Pfennigwerth

Soren G Gatermann

Felix Reichert

Michaela Diercke

Gyde Steffen

Doris Altmann

Annicka Reuss

Affiliations

Soon will be listed here.

Abstract

Background: Since May 2016, infection and colonisation with carbapenem non-susceptible Acinetobacter spp. (CRA) and Enterobacterales (CRE) have to be notified to health authorities in Germany. The aim of our study was to assess the epidemiology of CRA and CRE from 2017 to 2019 in Germany, to identify risk groups and to determine geographical differences of CRA and CRE notifications.

Methods: Cases were notified from laboratories to local public health authorities and forwarded to state and national level. Non-susceptibility was defined as intermediate or resistant to ertapenem, imipenem, or meropenem excluding intrinsic bacterial resistance or the detection of a carbapenemase gene. We analysed CRA and CRE notifications from 2017, 2018 and 2019 per 100,000 inhabitants (notification incidence), regarding their demographic, clinical and laboratory information. The effect of regional hospital-density on CRA and CRE notification incidence was estimated using negative binomial regression.

Results: From 2017 to 2019, 2278 CRA and 12,282 CRE cases were notified in Germany. CRA and CRE cases did not differ regarding demographic and clinical information, e.g. proportion infected. The notification incidence of CRA declined slightly from 0.95 in 2017 to 0.86 in 2019, whereas CRE increased from 4.23 in 2017 to 5.72 in 2019. The highest CRA and CRE notification incidences were found in the age groups above 70 years. Infants below 1 year showed a high CRE notification incidence, too. Notification incidences varied between 0.10 and 2.86 for CRA and between 1.49 and 9.99 for CRE by federal state. The notification incidence of CRA and CRE cases increased with each additional hospital per district.

Conclusion: The notification incidence of CRA and CRE varied geographically and was correlated with the number of hospitals.The results support the assumption that hospitals are the main driver for higher CRE and CRA incidence. Preventive strategies and early control measures should target older age groups and newborns and areas with a high incidence.

Citing Articles

Gastrointestinal carriage of carbapenemase-producing enterobacterales among inpatient and outpatient children in Kenya.

Githii S, Maingi J, Nyaga T, Ndungu C, Nyongesa K, Musyoki A Sci Rep. 2024; 14(1):30684.

PMID: 39730388 PMC: 11680766. DOI: 10.1038/s41598-024-78059-1.

Leveraging local public health to advance antimicrobial stewardship (AMS) implementation and mitigate antimicrobial resistance (AMR): a scoping review.

Leung V, Ashiru-Oredope D, Hicks L, Kabbani S, Aloosh M, Armstrong I JAC Antimicrob Resist. 2024; 6(6):dlae187.

PMID: 39698503 PMC: 11651725. DOI: 10.1093/jacamr/dlae187.

Molecular characteristics and evaluation of the phenotypic detection of carbapenemases among and via whole genome sequencing.

Liang B, Chen Y, Liang Z, Li X, Cai H, Lai H Front Cell Infect Microbiol. 2024; 14:1357289.

PMID: 39027138 PMC: 11254758. DOI: 10.3389/fcimb.2024.1357289.

[Therapy-relevant antibiotic resistances in a One Health context].

Werner G, Abu Sin M, Bahrs C, Brogden S, Fessler A, Hagel S Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2023; 66(6):628-643.

PMID: 37184673 PMC: 10261244. DOI: 10.1007/s00103-023-03713-4.

References

Ayobami O, Willrich N, Suwono B, Eckmanns T, Markwart R . The epidemiology of carbapenem-non-susceptible Acinetobacter species in Europe: analysis of EARS-Net data from 2013 to 2017. Antimicrob Resist Infect Control. 2020; 9(1):89. PMC: 7304165. DOI: 10.1186/s13756-020-00750-5. View

Nordmann P, Naas T, Poirel L . Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011; 17(10):1791-8. PMC: 3310682. DOI: 10.3201/eid1710.110655. View

Tacconelli E, Cataldo M, Dancer S, de Angelis G, Falcone M, Frank U . ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2013; 20 Suppl 1:1-55. DOI: 10.1111/1469-0691.12427. View

Babu Rajendran N, Mutters N, Marasca G, Conti M, Sifakis F, Vuong C . Mandatory surveillance and outbreaks reporting of the WHO priority pathogens for research & discovery of new antibiotics in European countries. Clin Microbiol Infect. 2019; 26(7):943.e1-943.e6. DOI: 10.1016/j.cmi.2019.11.020. View

Kremer K, Kramer R, Neumann B, Haller S, Pfennigwerth N, Werner G . Rapid spread of OXA-244-producing ST38 in Germany: insights from an integrated molecular surveillance approach; 2017 to January 2020. Euro Surveill. 2020; 25(25). PMC: 7331143. DOI: 10.2807/1560-7917.ES.2020.25.25.2000923. View

Maechler F, Pena Diaz L, Schroder C, Geffers C, Behnke M, Gastmeier P . Prevalence of carbapenem-resistant organisms and other Gram-negative MDRO in German ICUs: first results from the national nosocomial infection surveillance system (KISS). Infection. 2014; 43(2):163-8. DOI: 10.1007/s15010-014-0701-6. View

Brolund A, Lagerqvist N, Byfors S, Struelens M, Monnet D, Albiger B . Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018. Euro Surveill. 2019; 24(9). PMC: 6402177. DOI: 10.2807/1560-7917.ES.2019.24.9.1900123. View

Livermore D, Oakton K, Carter M, Warner M . Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases. Antimicrob Agents Chemother. 2001; 45(10):2831-7. PMC: 90739. DOI: 10.1128/AAC.45.10.2831-2837.2001. View

Kelly A, Mathema B, Larson E . Carbapenem-resistant Enterobacteriaceae in the community: a scoping review. Int J Antimicrob Agents. 2017; 50(2):127-134. PMC: 5726257. DOI: 10.1016/j.ijantimicag.2017.03.012. View

10.

Trepanier P, Mallard K, Meunier D, Pike R, Brown D, Ashby J . Carbapenemase-producing Enterobacteriaceae in the UK: a national study (EuSCAPE-UK) on prevalence, incidence, laboratory detection methods and infection control measures. J Antimicrob Chemother. 2016; 72(2):596-603. DOI: 10.1093/jac/dkw414. View

11.

Temkin E, Adler A, Lerner A, Carmeli Y . Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. Ann N Y Acad Sci. 2014; 1323:22-42. DOI: 10.1111/nyas.12537. View

12.

. [Hygiene measures for infection or colonization with multidrug-resistant gram-negative bacilli. Commission recommendation for hospital hygiene and infection prevention (KRINKO) at the Robert Koch Institute (RKI)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012; 55(10):1311-54. DOI: 10.1007/s00103-012-1549-5. View

13.

Kleinkauf N, Hausemann A, Kempf V, Gottschalk R, Heudorf U . Burden of carbapenem-resistant organisms in the Frankfurt/Main Metropolitan Area in Germany 2012/2013 - first results and experiences after the introduction of legally mandated reporting. BMC Infect Dis. 2014; 14:446. PMC: 4143562. DOI: 10.1186/1471-2334-14-446. View

14.

Heudorf U, Gottschalk R, Exner M . [Mandatory reporting of antimicrobial-resistant pathogens. What should, what can be achieved? : assessment related to the particular facility seems crucial]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014; 57(11):1322-30. DOI: 10.1007/s00103-014-2046-9. View

15.

Becker L, Fuchs S, Pfeifer Y, Semmler T, Eckmanns T, Korr G . Whole Genome Sequence Analysis of CTX-M-15 Producing Isolates Allowed Dissecting a Polyclonal Outbreak Scenario. Front Microbiol. 2018; 9:322. PMC: 5829066. DOI: 10.3389/fmicb.2018.00322. View

16.

Guh A, Bulens S, Mu Y, Jacob J, Reno J, Scott J . Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013. JAMA. 2015; 314(14):1479-87. PMC: 6492240. DOI: 10.1001/jama.2015.12480. View

17.

Chung H, Yong D, Lee M . Mechanisms of ertapenem resistance in Enterobacteriaceae isolates in a tertiary university hospital. J Investig Med. 2016; 64(5):1042-9. DOI: 10.1136/jim-2016-000117. View

18.

Koppe U, von Laer A, Kroll L, Noll I, Feig M, Schneider M . Carbapenem non-susceptibility of isolates in hospitals from 2011 to 2016, data from the German Antimicrobial Resistance Surveillance (ARS). Antimicrob Resist Infect Control. 2018; 7:71. PMC: 5987571. DOI: 10.1186/s13756-018-0362-9. View

19.

Ayobami O, Willrich N, Harder T, Okeke I, Eckmanns T, Markwart R . The incidence and prevalence of hospital-acquired (carbapenem-resistant) in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis. Emerg Microbes Infect. 2019; 8(1):1747-1759. PMC: 6913636. DOI: 10.1080/22221751.2019.1698273. View

20.

Schweizer C, Bischoff P, Bender J, Kola A, Gastmeier P, Hummel M . Plasmid-Mediated Transmission of KPC-2 Carbapenemase in in Critically Ill Patients. Front Microbiol. 2019; 10:276. PMC: 6390000. DOI: 10.3389/fmicb.2019.00276. View